INTERVIEW: Korea’s OncoVenture Nurturing Oncology Innovation
This article was originally published in PharmAsia News
Executive Summary
In an exclusive interview with PharmAsia News, a senior executive of South Korea's National OncoVenture, which aims to increase support for immuno-oncology R&D projects amid the global boom in this sector, calls for more government support, collaborations and co-development among domestic pharmas, biotechs and researchers to develop globally competitive cancer drugs.
You may also be interested in...
A Peek Into Korean Bioventures’ Success Factors, Challenges
Amid a boom in IPOs and valuations, experts at a recent forum in Seoul took a look at some of the success factors and challenges behind the rapid growth of South Korea’s bioventure sector.
Korea Govt Partners With J&J To Bring In Local JLABS Site
In collaboration with the national health ministry, J&J’s JLAB program is coming to South Korea as its third destination in Asia, underscoring the country’s increasing need to access multinationals’ know-how and its growing impact on the global biotech landscape and innovation.
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.